JP7078552B2 - α－シヌクレインに対する抗体およびその使用 - Google Patents

α－シヌクレインに対する抗体およびその使用 Download PDF

Info

Publication number
JP7078552B2
JP7078552B2 JP2018563050A JP2018563050A JP7078552B2 JP 7078552 B2 JP7078552 B2 JP 7078552B2 JP 2018563050 A JP2018563050 A JP 2018563050A JP 2018563050 A JP2018563050 A JP 2018563050A JP 7078552 B2 JP7078552 B2 JP 7078552B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
synuclein
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527194A (ja
JP2019527194A5 (enExample
Inventor
パーキンソン，マイケル
スコフィールド，ダーレン
アービング，ローレイン
トム，ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2019527194A publication Critical patent/JP2019527194A/ja
Publication of JP2019527194A5 publication Critical patent/JP2019527194A5/ja
Priority to JP2022082099A priority Critical patent/JP2022110117A/ja
Application granted granted Critical
Publication of JP7078552B2 publication Critical patent/JP7078552B2/ja
Priority to JP2024103562A priority patent/JP2024123247A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
JP2018563050A 2016-06-02 2017-06-01 α－シヌクレインに対する抗体およびその使用 Active JP7078552B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022082099A JP2022110117A (ja) 2016-06-02 2022-05-19 α－シヌクレインに対する抗体およびその使用
JP2024103562A JP2024123247A (ja) 2016-06-02 2024-06-27 α－シヌクレインに対する抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344746P 2016-06-02 2016-06-02
US62/344,746 2016-06-02
PCT/EP2017/063406 WO2017207739A1 (en) 2016-06-02 2017-06-01 Antibodies to alpha-synuclein and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022082099A Division JP2022110117A (ja) 2016-06-02 2022-05-19 α－シヌクレインに対する抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2019527194A JP2019527194A (ja) 2019-09-26
JP2019527194A5 JP2019527194A5 (enExample) 2020-07-09
JP7078552B2 true JP7078552B2 (ja) 2022-05-31

Family

ID=59021492

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563050A Active JP7078552B2 (ja) 2016-06-02 2017-06-01 α－シヌクレインに対する抗体およびその使用
JP2022082099A Pending JP2022110117A (ja) 2016-06-02 2022-05-19 α－シヌクレインに対する抗体およびその使用
JP2024103562A Pending JP2024123247A (ja) 2016-06-02 2024-06-27 α－シヌクレインに対する抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022082099A Pending JP2022110117A (ja) 2016-06-02 2022-05-19 α－シヌクレインに対する抗体およびその使用
JP2024103562A Pending JP2024123247A (ja) 2016-06-02 2024-06-27 α－シヌクレインに対する抗体およびその使用

Country Status (38)

Country Link
US (5) US10160800B2 (enExample)
EP (2) EP4000632A1 (enExample)
JP (3) JP7078552B2 (enExample)
KR (1) KR102499438B1 (enExample)
CN (2) CN109475616B (enExample)
AR (1) AR108663A1 (enExample)
AU (2) AU2017272804B2 (enExample)
BR (1) BR112018074978A2 (enExample)
CA (1) CA3025987A1 (enExample)
CL (1) CL2018003438A1 (enExample)
CO (1) CO2018014010A2 (enExample)
CY (1) CY1124896T1 (enExample)
DK (1) DK3463435T3 (enExample)
EA (2) EA202191380A1 (enExample)
EC (1) ECSP18096095A (enExample)
ES (1) ES2903402T3 (enExample)
GE (1) GEP20217253B (enExample)
HR (1) HRP20211935T1 (enExample)
HU (1) HUE057214T2 (enExample)
IL (1) IL263243A (enExample)
LT (1) LT3463435T (enExample)
MA (1) MA45125B1 (enExample)
MD (1) MD3463435T2 (enExample)
MX (1) MX393740B (enExample)
MY (1) MY188183A (enExample)
NZ (1) NZ748616A (enExample)
PE (2) PE20250392A1 (enExample)
PH (1) PH12018502538A1 (enExample)
PL (1) PL3463435T3 (enExample)
PT (1) PT3463435T (enExample)
RS (1) RS62682B1 (enExample)
SG (1) SG11201810420YA (enExample)
SI (1) SI3463435T1 (enExample)
SM (1) SMT202200008T1 (enExample)
TW (2) TWI765890B (enExample)
UA (1) UA124733C2 (enExample)
WO (1) WO2017207739A1 (enExample)
ZA (1) ZA201808582B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10889635B2 (en) * 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EA202190807A1 (ru) * 2018-10-19 2021-08-06 Янссен Вэксинс Энд Превеншн Б.В. Антитела к синуклеину
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
US20220298231A1 (en) 2019-04-18 2022-09-22 Ac Immune Sa Novel Molecules for Therapy and Diagnosis
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
AU2020350769A1 (en) 2019-09-20 2022-03-31 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
KR102239512B1 (ko) * 2020-09-10 2021-04-12 서울대학교산학협력단 다중기능성 마이크로캡슐 조성물 및 그 제조방법
US20250320283A1 (en) 2020-10-16 2025-10-16 Ac Immune Sa Antibodies Binding to Alpha-Synuclein for Therapy and Diagnosis
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CN113912716B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 针对α-突触核蛋白抗原的抗体及其应用
KR20250148576A (ko) 2022-12-29 2025-10-14 아스트라제네카 아베 알파-시누클레인병증을 치료하기 위한 조성물 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526028A (ja) 2007-02-23 2010-07-29 エラン・フアーマシユーチカルズ・インコーポレーテツド シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
JP2013525266A (ja) 2010-02-26 2013-06-20 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
JP2016511254A (ja) 2013-02-28 2016-04-14 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ アルファ−シヌクレイン抗体及びその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
ES2640669T3 (es) 2003-05-19 2017-11-03 Prothena Biosciences Limited Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
US20090047300A1 (en) 2005-09-27 2009-02-19 Abedelnasser Abulrob Blood-brain barrier epitopes and uses thereof
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4934074B2 (ja) 2007-03-07 2012-05-16 株式会社アルファ スイッチ固定構造
LT2282758T (lt) 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
JP4654348B1 (ja) 2010-02-23 2011-03-16 多摩川精機株式会社 検出装置用巻線の正弦波巻線方法
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
CN107880123A (zh) 2011-10-28 2018-04-06 普罗典娜生物科学有限公司 识别α‑突触核蛋白的人源化抗体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
PT3071597T (pt) * 2013-11-21 2020-10-08 Hoffmann La Roche Anticorpos anti-alfa-sinucleína e métodos de utilização
CN112778418B (zh) 2014-11-10 2025-04-22 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526028A (ja) 2007-02-23 2010-07-29 エラン・フアーマシユーチカルズ・インコーポレーテツド シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
JP2013525266A (ja) 2010-02-26 2013-06-20 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
JP2016511254A (ja) 2013-02-28 2016-04-14 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ アルファ−シヌクレイン抗体及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Neurosci, 2014 Jul 9, vol. 34, no. 28, pp. 9441-9454

Also Published As

Publication number Publication date
MY188183A (en) 2021-11-24
US20210179698A1 (en) 2021-06-17
ES2903402T3 (es) 2022-04-01
US20250263477A1 (en) 2025-08-21
US10160800B2 (en) 2018-12-25
TW201802119A (zh) 2018-01-16
CN109475616A (zh) 2019-03-15
RS62682B1 (sr) 2021-12-31
LT3463435T (lt) 2021-12-27
SMT202200008T1 (it) 2022-03-21
AU2024200601A1 (en) 2024-04-18
EP3463435A1 (en) 2019-04-10
PE20250392A1 (es) 2025-02-11
JP2024123247A (ja) 2024-09-10
CN109475616B (zh) 2022-10-18
EP3463435B1 (en) 2021-10-13
SI3463435T1 (sl) 2022-02-28
NZ748616A (en) 2025-08-29
MD3463435T2 (ro) 2022-03-31
AR108663A1 (es) 2018-09-12
SG11201810420YA (en) 2018-12-28
CN116120445A (zh) 2023-05-16
HRP20211935T1 (hr) 2022-03-18
ZA201808582B (en) 2021-08-25
US20190276522A1 (en) 2019-09-12
HUE057214T2 (hu) 2022-04-28
CY1124896T1 (el) 2023-01-05
PL3463435T3 (pl) 2022-02-14
KR102499438B1 (ko) 2023-02-14
WO2017207739A1 (en) 2017-12-07
US20230331830A1 (en) 2023-10-19
UA124733C2 (uk) 2021-11-10
AU2017272804A1 (en) 2018-12-13
US11560424B2 (en) 2023-01-24
PT3463435T (pt) 2021-11-22
US20180002411A1 (en) 2018-01-04
JP2019527194A (ja) 2019-09-26
ECSP18096095A (es) 2019-01-31
KR20190013923A (ko) 2019-02-11
JP2022110117A (ja) 2022-07-28
AU2017272804B2 (en) 2023-11-23
PH12018502538A1 (en) 2019-04-08
PE20190440A1 (es) 2019-03-27
MA45125B1 (fr) 2021-11-30
MA45125A (fr) 2021-06-02
EA038358B1 (ru) 2021-08-13
GEP20217253B (en) 2021-05-13
CL2018003438A1 (es) 2019-03-22
IL263243A (en) 2018-12-31
TW202309093A (zh) 2023-03-01
EA202191380A1 (ru) 2021-08-26
CA3025987A1 (en) 2017-12-07
EA201892548A1 (ru) 2019-06-28
MX393740B (es) 2025-03-24
US10889639B2 (en) 2021-01-12
EP4000632A1 (en) 2022-05-25
BR112018074978A2 (pt) 2019-03-12
MX2018014456A (es) 2019-08-12
TWI765890B (zh) 2022-06-01
DK3463435T3 (da) 2021-11-22
CO2018014010A2 (es) 2019-01-18

Similar Documents

Publication Publication Date Title
JP7078552B2 (ja) α－シヌクレインに対する抗体およびその使用
JP7138322B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
JP7217229B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
HK40072606A (en) Antibodies to alpha-synuclein and uses thereof
HK40007492B (en) Antibodies to alpha-synuclein and uses thereof
US20230357386A1 (en) Anti-epha4 antibody
HK40005896B (zh) 针对α-突触核蛋白的抗体及其用途
HK40005896A (en) Antibodies to alpha-synuclein and uses thereof
JP2024506391A (ja) タウを認識する抗体の使用方法
EA048795B1 (ru) Антитело к epha4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7078552

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250